119 related articles for article (PubMed ID: 32536252)
1. The effect of the
Fatjó-Vilas M; Soler J; Ibáñez MI; Moya-Higueras J; Ortet G; Guardiola-Ripoll M; Fañanás L; Arias B
J Psychopharmacol; 2020 Sep; 34(9):990-998. PubMed ID: 32536252
[TBL] [Abstract][Full Text] [Related]
2. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder.
van Winkel R; van Beveren NJ; Simons C;
Neuropsychopharmacology; 2011 Nov; 36(12):2529-37. PubMed ID: 21775978
[TBL] [Abstract][Full Text] [Related]
3. Cannabis and a lower BMI in psychosis: What is the role of AKT1?
Liemburg EJ; Bruins J; van Beveren N; Islam MA; Alizadeh BZ;
Schizophr Res; 2016 Oct; 176(2-3):95-99. PubMed ID: 27554198
[TBL] [Abstract][Full Text] [Related]
4. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users.
Di Forti M; Iyegbe C; Sallis H; Kolliakou A; Falcone MA; Paparelli A; Sirianni M; La Cascia C; Stilo SA; Marques TR; Handley R; Mondelli V; Dazzan P; Pariante C; David AS; Morgan C; Powell J; Murray RM
Biol Psychiatry; 2012 Nov; 72(10):811-6. PubMed ID: 22831980
[TBL] [Abstract][Full Text] [Related]
5. AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers.
Morgan CJ; Freeman TP; Powell J; Curran HV
Transl Psychiatry; 2016 Feb; 6(2):e738. PubMed ID: 26882038
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase B (AKT1) genotype mediates sensitivity to cannabis-induced impairments in psychomotor control.
Bhattacharyya S; Iyegbe C; Atakan Z; Martin-Santos R; Crippa JA; Xu X; Williams S; Brammer M; Rubia K; Prata D; Collier DA; McGuire PK
Psychol Med; 2014 Nov; 44(15):3315-28. PubMed ID: 25065544
[TBL] [Abstract][Full Text] [Related]
7. The AKT1 gene is associated with attention and brain morphology in schizophrenia.
Ohi K; Hashimoto R; Yasuda Y; Fukumoto M; Nemoto K; Ohnishi T; Yamamori H; Takahashi H; Iike N; Kamino K; Yoshida T; Azechi M; Ikezawa K; Tanimukai H; Tagami S; Morihara T; Okochi M; Tanaka T; Kudo T; Iwase M; Kazui H; Takeda M
World J Biol Psychiatry; 2013 Mar; 14(2):100-13. PubMed ID: 22150081
[TBL] [Abstract][Full Text] [Related]
8. [Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders].
Liraud F; Verdoux H
Encephale; 2002; 28(2):160-8. PubMed ID: 11972143
[TBL] [Abstract][Full Text] [Related]
9. DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia.
Blasi G; Napolitano F; Ursini G; Taurisano P; Romano R; Caforio G; Fazio L; Gelao B; Di Giorgio A; Iacovelli L; Sinibaldi L; Popolizio T; Usiello A; Bertolino A
Proc Natl Acad Sci U S A; 2011 Jan; 108(3):1158-63. PubMed ID: 21187413
[TBL] [Abstract][Full Text] [Related]
10. Association of AKT1 with verbal learning, verbal memory, and regional cortical gray matter density in twins.
Pietiläinen OP; Paunio T; Loukola A; Tuulio-Henriksson A; Kieseppä T; Thompson P; Toga AW; van Erp TG; Silventoinen K; Soronen P; Hennah W; Turunen JA; Wedenoja J; Palo OM; Silander K; Lönnqvist J; Kaprio J; Cannon TD; Peltonen L
Am J Med Genet B Neuropsychiatr Genet; 2009 Jul; 150B(5):683-92. PubMed ID: 19051289
[TBL] [Abstract][Full Text] [Related]
11. Cannabis involvement and neuropsychological performance: findings from the Human Connectome Project.
Petker T; Owens MM; Amlung MT; Oshri A; Sweet LH; MacKillop J
J Psychiatry Neurosci; 2019 Nov; 44(6):414-422. PubMed ID: 31245962
[TBL] [Abstract][Full Text] [Related]
12. Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?
Hindocha C; Quattrone D; Freeman TP; Murray RM; Mondelli V; Breen G; Curtis C; Morgan CJA; Valerie Curran H; Di Forti M
Transl Psychiatry; 2020 May; 10(1):143. PubMed ID: 32398646
[TBL] [Abstract][Full Text] [Related]
13. The interaction between the ZNF804A gene and cannabis use on the risk of psychosis in a non-clinical sample.
Soler J; Arias B; Moya J; Ibáñez MI; Ortet G; Fañanás L; Fatjó-Vilas M
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():174-180. PubMed ID: 30118824
[TBL] [Abstract][Full Text] [Related]
14. The effect of interactions between genetics and cannabis use on neurocognition. A review.
Cosker E; Schwitzer T; Ramoz N; Ligier F; Lalanne L; Gorwood P; Schwan R; Laprévote V
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Mar; 82():95-106. PubMed ID: 29191570
[TBL] [Abstract][Full Text] [Related]
15. Cannabis use and cognitive function in first episode psychosis: differential effect of heavy use.
Núñez C; Ochoa S; Huerta-Ramos E; Baños I; Barajas A; Dolz M; Sánchez B; Del Cacho N; ; Usall J
Psychopharmacology (Berl); 2016 Mar; 233(5):809-21. PubMed ID: 26621349
[TBL] [Abstract][Full Text] [Related]
16. Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings.
Meijer JH; Dekker N; Koeter MW; Quee PJ; van Beveren NJ; Meijer CJ;
Psychol Med; 2012 Apr; 42(4):705-16. PubMed ID: 21899795
[TBL] [Abstract][Full Text] [Related]
17. Auditory event-related potentials (P3) and cognitive performance in recreational ecstasy polydrug users: evidence from a 12-month longitudinal study.
de Sola S; Tarancón T; Peña-Casanova J; Espadaler JM; Langohr K; Poudevida S; Farré M; Verdejo-García A; de la Torre R
Psychopharmacology (Berl); 2008 Oct; 200(3):425-37. PubMed ID: 18581098
[TBL] [Abstract][Full Text] [Related]
18. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
19. Neuropsychological performance in young adults with cannabis use disorder.
Selamoglu A; Langley C; Crean R; Savulich G; Cormack F; Sahakian BJ; Mason B
J Psychopharmacol; 2021 Nov; 35(11):1349-1355. PubMed ID: 34694178
[TBL] [Abstract][Full Text] [Related]
20. Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls.
Nicodemus KK; Law AJ; Radulescu E; Luna A; Kolachana B; Vakkalanka R; Rujescu D; Giegling I; Straub RE; McGee K; Gold B; Dean M; Muglia P; Callicott JH; Tan HY; Weinberger DR
Arch Gen Psychiatry; 2010 Oct; 67(10):991-1001. PubMed ID: 20921115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
